Ertumaxomab

Drug Profile

Ertumaxomab

Alternative Names: Anti-CD3 X anti-HER-2/neu; Rexomab®; Rexomun

Latest Information Update: 08 Sep 2011

Price : $50

At a glance

  • Originator TRION Pharma
  • Developer Fresenius Biotech; TRION Pharma
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Immunostimulants; Macrophage stimulants; Natural killer cell stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer

Most Recent Events

  • 14 Aug 2009 Discontinued - Phase-II for Breast cancer in Europe (IV)
  • 03 Jun 2008 Pharmacodynamics data from a preclinical study in breast cancer presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO-2008)
  • 12 Jul 2006 Phase-II clinical trials in Breast cancer in Europe (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top